The U.S. Food and Drug

Administration (FDA) has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children age 16 and older.

Oravig, which adheres to the gum, utilizes innovative buccal tablet technology enabling once-daily dosing that delivers miconazole directly at the local site of infection throughout the day with minimal systemic absorption. Oravig is easy-to-use and provides patients with a flavorless, odorless and convenient treatment option that does not interfere with daily activities such as eating and drinking.

Oravig Medication Guide

Read the Patient Information that comes with Oravig before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor or about your medical condition or your treatment.

 
What is Oravig

Oravig is a prescription antifungal medicine used in adults to treat fungal (yeast) infections of the mouth and the throat. It is not known if Oravig is safe and effective in children under the age of 16 years. It is not known if children can follow the instructions on what to do with the buccal tablet. In younger children, there is a possible risk of choking.